Psych Editorial
  • Home
  • Contact

Meet the Pfizer Executive Leadership Team: Frank D’ Amelio

Meet the Pfizer Executive Leadership Team: Frank D’ Amelio

Frank D’Amelio is the Executive Vice President, Business Operations & Chief Financial Officer of Pfizer, responsible for finance, business development and business operations, including IT, procurement and real estate.

Before joining the company in September 2007, he was Senior Executive Vice President of Integration and Chief Administrative Officer of Alcatel-Lucent, responsible for the integration of the Alcatel-Lucent merger, in addition to the supply chain, information technology, real estate, marketing, legal and the U.S. labor relations operations of the company.

Prior to the merger of Alcatel and Lucent Technologies in 2006, Frank was the Chief Operating Officer of Lucent Technologies, responsible for leading business operations, including sales, the product groups, the services business, the supply chain, information technology operations, human resources and labor relations. In 2001, he was appointed Executive Vice President and Chief Financial Officer of Lucent, where he helped lead the company through one of the most challenging periods in the telecom industry’s history and returned the company to profitability. In this role, Frank was responsible for management and oversight of all financial, accounting, real estate and labor relations operations, and the operational aspects of the legal and human resources organizations.

When Lucent was spun off from AT&T in 1996, Frank helped create the new company financially as the CFO of Lucent’s Network Systems Business and was a critical member of the team that met with investors around the world during Lucent’s initial public offering. After the IPO, he was appointed the Group President of Lucent’s Switching Solutions Group, where he led the manufacturing, research and development, marketing and product management of Lucent’s multibillion-dollar, global Switching, Access and Application Software businesses.

Born and raised in New Jersey, Frank earned his MBA in Finance from St. John’s University and his bachelor’s degree in Accounting from St. Peter’s College. He started his career in 1979 at Bell Labs, holding a variety of financial, accounting and general management positions, and moved within AT&T, commanding a series of positions with increasing responsibility.

In 2005, 2006, 2011 and 2012, Frank was ranked among America’s top CFOs by Institutional Investor magazine, and in 2002, he was selected one of the top 10 leaders in his field by Treasury & Risk Management magazine.

He serves on the Board of Directors of Humana, Inc. as chair of the Audit Committee, the Board of the Independent College Fund of New Jersey and the Gillen-Brewer School.

Source: Pfizer Press Releases – Meet Our Executives

Related Posts

Takeda Pharmaceuticals

Takeda and Lundbeck Announce FDA Approval of Brintellix™ (vortioxetine) for Treatment of Adults with Major Depressive Disorder

Eli Lilly and Co., Executive Bios

Meet the Executive Eli Lilly and Company Leadership Team: Fionnuala M. Walsh

Eli Lilly and Co., Executive Bios

Meet the Executive Eli Lilly and Company Leadership Team: Jacques Tapiero

News & Views

  • Now Accepting Content
  • Takeda and Lundbeck Announce FDA Approval of Brintellix™ (vortioxetine) for Treatment of Adults with Major Depressive Disorder
  • Introducing the New Kid on the Block to Treat Depression: “Brintellix”.
  • Meet the Executive Eli Lilly and Company Leadership Team: Fionnuala M. Walsh
  • Meet the Executive Eli Lilly and Company Leadership Team: Jacques Tapiero
Psych Editorial
Copyright © PhysicianEditorial.com
All Rights Reserved!